TREATT

Title
TREATT: Trial to Evaluate Anti-fibrinolytic Therapy in Thrombocytopenia
TREATT: Trial to Evaluate Anti-fibrinolytic Therapy in Thrombocytopenia
Chief Investigators
TREATT: Trial to Evaluate Anti-fibrinolytic Therapy in Thrombocytopenia
Dr Simon Stanworth and Dr Lise Estcourt
Location/Institution
TREATT: Trial to Evaluate Anti-fibrinolytic Therapy in Thrombocytopenia
Oxford University Hospitals NHS Foundation Trust
Funder
TREATT: Trial to Evaluate Anti-fibrinolytic Therapy in Thrombocytopenia
NHSBT Research and Development Committee
Research Theme
TREATT: Trial to Evaluate Anti-fibrinolytic Therapy in Thrombocytopenia
Patient Blood Management
Lay Summary
TREATT: Trial to Evaluate Anti-fibrinolytic Therapy in Thrombocytopenia

Anti-fibrinolytic drugs such as tranexamic acid are medications which help to stabilise blood clots that form after bleeding. They have been shown to reduce the chances of both further bleeding and the need for blood transfusions.

The TREATT clinical trial aims to test whether using tranexamic acid will reduce bleeding in patients who have very low platelet counts due to their disease (e.g. a haematological malignancy such as lymphoma, leukaemia, or myeloma) or its treatment. TREATT is currently recruiting eligible patients in sites around the UK, with patients being randomised to receive tranexamic acid or not during the period of greatest risk of bleeding.

The main aim of the clinical trial is to determine whether anti-fibrinolytics are effective in these patient groups.

Visit the trial website